zansecimab

Home
Ligands
zansecimab

GtoPdb Ligand ID: 11334

Synonyms: LY-3127804 | LY3127804

Comment: Zansecimab (LY3127804) is a humanised IgG4 monoclonal antibody that targets angiopoietin 2 (Ang2). It was designed and developed by Eli Lilly to block angiogenesis as an anti-tumour mechanism. As Ang2 is elevated in acute respiratory distress syndrome (ARDS), Eli Lilly chose to evaluate LY3127804 in patients hospitalised with COVID-19 pneumonia, to ascertain if this approach could reduce the risk of developing ARDS in at risk patients. The COVID study was terminated for futility after around 6 months.
The peptide chain sequences of zansecimab (from its INN submission) are identical to sequences claimed in Eli Lilly's patent WO2015179166A1: sequences 2 and 4 comprise the heavy and light chains of the mAb designated as 'Antibody A' in the patent [1].

References
1. Leung DDM, Xu J. (2015) Ang2 antibodies. Patent number: WO2015179166A1. Assignee: Eli Lilly And Company. Priority date: 19/05/2014. Publication date: 26/11/2015.
2. Martin-Liberal J, Hollebecque A, Aftimos P, Jungels C, Martin-Romano P, Rodon J, Kremer JD, Zhang W, Bendell J. (2020) First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours. Br J Cancer, 123 (8): 1235-1243. [PMID:32741971]

References

1. Leung DDM, Xu J. (2015)
Ang2 antibodies.
Patent number: WO2015179166A1. Assignee: Eli Lilly And Company. Priority date: 19/05/2014. Publication date: 26/11/2015.

2. Martin-Liberal J, Hollebecque A, Aftimos P, Jungels C, Martin-Romano P, Rodon J, Kremer JD, Zhang W, Bendell J. (2020)
First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours.
Br J Cancer, 123 (8): 1235-1243. [PMID:32741971]